Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31066863.
- Also identified by DOI 10.1001/jamacardio.2019.1189 and PMC identifier 6506905.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study uses in vitro assays and a mouse model to investigate antibacterial properties of ticagrelor to follow up findings from 2 clinical trials that showed patients taking ticagrelor for cardiovascular disease had a lower risk of infection-related death and improved lung function compared with patients treated with clopidogrel.
Medical subject headings
- Anti-Bacterial Agents
- Biofilms
- Gram-Positive Bacteria
- Purinergic P2Y Receptor Antagonists
- Ticagrelor